-
221.
公开(公告)号:US20230348563A1
公开(公告)日:2023-11-02
申请号:US18315183
申请日:2023-05-10
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC: C07K14/74 , A61K38/06 , C12N9/64 , C12N5/0783 , C07K16/30 , C07K14/47 , A61K39/00 , C07K16/28 , A61K45/06 , C07K14/00 , C07K7/06 , C07K7/02 , G01N33/50 , G01N33/566 , C07K16/18 , A61K38/08 , C07K14/725 , G01N33/569 , A61K38/17 , C12Q1/6886 , A01N37/46
CPC classification number: C07K14/70539 , A01N37/46 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12Q1/6886 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , A61K38/00 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N2501/998 , C12N2502/11 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539
Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
222.
公开(公告)号:US20230235015A1
公开(公告)日:2023-07-27
申请号:US18052796
申请日:2022-11-04
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC: C07K14/74 , A61K38/06 , C12N9/64 , C12N5/0783 , C07K16/30 , C07K14/47 , A61K39/00 , C07K16/28 , A61K45/06 , C07K14/00 , C07K7/06 , C07K7/02 , G01N33/50 , G01N33/566 , C07K16/18 , A61K38/08 , C07K14/725 , G01N33/569 , A61K38/17 , C12Q1/6886 , A01N37/46
CPC classification number: C07K14/70539 , A61K38/06 , C12N9/6491 , C12N5/0636 , C07K16/30 , C07K14/4748 , A61K39/0011 , C07K16/2833 , A61K45/06 , C07K14/001 , C07K7/06 , C07K7/02 , G01N33/505 , G01N33/566 , G01N33/5088 , A61K39/0005 , C07K16/18 , C07K14/47 , C12N5/0638 , A61K38/08 , C07K14/7051 , G01N33/56972 , C07K14/4702 , A61K38/1774 , C12Q1/6886 , G01N33/56977 , A01N37/46 , C07K2317/34 , C12Q2600/106 , C12Q2600/158 , G01N2333/7051 , A61K2039/54 , G01N2333/70539 , C07K2317/31 , C07K2317/24 , G01N2333/70503 , C07K2319/00 , C07K2319/40 , C12N2502/11 , A61K2039/572 , G01N2333/47 , C12N2501/998 , C12Y304/24 , A61K2039/57 , A61K2039/585 , A61K38/00
Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
223.
公开(公告)号:US20230203113A1
公开(公告)日:2023-06-29
申请号:US18063396
申请日:2022-12-08
Applicant: Immatics Biotechnologies GmbH
Inventor: Oliver SCHOOR , Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/47 , A61P35/00 , A61K39/00 , C07K14/74 , C07K16/28 , C12N5/0783 , C12N15/113 , C07K14/725 , C07K16/30
CPC classification number: C07K14/4748 , A61K39/0011 , A61K39/001154 , A61P35/00 , C07K14/7051 , C07K14/70539 , C07K16/2833 , C07K16/3046 , C07K16/3076 , C12N5/0636 , C12N15/1138 , A61K2039/5154 , A61K2039/5158 , C07K2317/34 , C12N2310/16 , C12N2501/50
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
224.
公开(公告)号:US20230113246A1
公开(公告)日:2023-04-13
申请号:US18051225
申请日:2022-10-31
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC: C07K14/74 , A61K38/06 , C12N9/64 , C12N5/0783 , C07K16/30 , C07K14/47 , A61K39/00 , C07K16/28 , A61K45/06 , C07K14/00 , C07K7/06 , C07K7/02 , G01N33/50 , G01N33/566 , C07K16/18 , A61K38/08 , C07K14/725 , G01N33/569 , A61K38/17 , C12Q1/6886 , A01N37/46
Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
225.
公开(公告)号:US20230101093A1
公开(公告)日:2023-03-30
申请号:US17932836
申请日:2022-09-16
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Helen HOERZER , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , A61K38/17 , C07K7/06 , C07K14/47 , C07K14/725 , C12N15/115 , A61P35/02 , A61K38/08 , A61K35/17 , C07K16/28 , C07K16/00 , C07K14/72 , A61P35/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
226.
公开(公告)号:US20230087025A1
公开(公告)日:2023-03-23
申请号:US18050701
申请日:2022-10-28
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC: C07K14/74 , A61K38/06 , C12N9/64 , C12N5/0783 , C07K16/30 , C07K14/47 , A61K39/00 , C07K16/28 , A61K45/06 , C07K14/00 , C07K7/06 , C07K7/02 , G01N33/50 , G01N33/566 , C07K16/18 , A61K38/08 , C07K14/725 , G01N33/569 , A61K38/17 , C12Q1/6886 , A01N37/46
Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
227.
公开(公告)号:US20230065320A1
公开(公告)日:2023-03-02
申请号:US17937165
申请日:2022-09-30
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor: Toni WEINSCHENK , Jens FRITSCHE , Harpreet SINGH , Andrea MAHR , Martina OTT , Claudia WAGNER , Oliver SCHOOR
IPC: A61K39/00 , C07K14/47 , C07K14/74 , C07K16/18 , C12N15/115
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20220356220A1
公开(公告)日:2022-11-10
申请号:US17345457
申请日:2021-06-11
Applicant: Immatics Biotechnologies GmbH
Inventor: Oliver SCHOOR , Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/47 , A61P35/00 , A61K39/00 , C07K14/74 , C07K16/28 , C12N5/0783 , C12N15/113 , C07K14/725 , C07K16/30
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20220339272A1
公开(公告)日:2022-10-27
申请号:US17853344
申请日:2022-06-29
Applicant: Immatics Biotechnologies GmbH
Inventor: Toni WEINSCHENK , Andrea MAHR , Jens FRITSCHE , Phillip MUELLER , Anita WIEBE , Sarah KUTSCHER
IPC: A61K39/00 , A61K35/17 , G01N33/68 , C07K14/74 , C07K14/435 , C12N15/115 , C12N5/0783 , C07K14/725 , A61K51/10 , A61K38/04 , C07K7/00 , C07K7/08 , C07K16/18 , C07K7/06
Abstract: A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.
-
230.
公开(公告)号:US20220280623A1
公开(公告)日:2022-09-08
申请号:US17743778
申请日:2022-05-13
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K16/28 , C07K14/705 , C07K7/08 , G16B25/10 , C12N9/12 , C07K7/06 , C07K16/40 , C07K14/71 , C07K14/47 , C12N15/115 , C12N9/02 , C12N5/0783 , C12Q1/6886 , C07K16/30 , G16B25/00 , C07K14/72 , C07K16/18 , C07K16/38 , G01N33/574 , C07K14/725 , C07K14/81
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-